Courses / Disease Modeling And Target Discovery
Disease Modeling And Target Discovery
This course is presented to you by Insilico Medicine, an artificial intelligence-driven pharma-technology company that focuses on accelerating drug discovery and development. Insilico Medicine develops the PHARMA.AI platform to discover novel targets, design novel molecules and maximize chances of successfully conducting clinical trials. Currently Insilico Medicine has 29 targets participating in 31 programs in a diversified pipeline covering fibrosis, oncology, COVID-19, aging and other indications.
HDR UK has brought Insilico Medicine's excellent course on Disease Modelling and Target Discovery to Futures. This course features seven lessons, each with their own bitesize videos for you to gain a better understanding of disease modelling.
Disease modelling and target discovery are critical areas in biomedical research that involve using computational and experimental approaches to gain insights into the causes of diseases and identify potential targets for drug development. With the increasing prevalence of complex diseases such as cancer, Alzheimer's, and diabetes, there is a growing need for researchers and healthcare professionals with expertise in these areas.
The course content is composed of seven lectures covering key topics such as target selection criteria, the use of computational approaches, and emerging trends. A special emphasis is placed on case studies to illustrate the practical application of the concepts covered. In particular, course participants have the opportunity to freely explore a demo edition of PandaOmics, a popular commercial tool for target discovery and omics data analysis.
The target audience for this course is individuals interested in drug discovery, biomedical research, and healthcare innovation such as researchers, scientists, and professionals in the pharmaceutical industry. The course is especially suitable for students pursuing a degree in molecular biology, chemistry, or related fields who want to understand the aspects of initial but key steps in drug development. They will see how fundamental science can be applied to the development of novel therapeutics. Specialists in data analysis, machine learning, and natural language processing may also be interested in this course, since these areas are actively used in drug development.
The course will provide them with knowledge about problem setting and potential applications as well as give an intro to the underlying biology. Overall, our course can initiate or boost your career in big pharma or small biotech companies. Join us today and take the first step toward making a positive impact on human health!
Introduction
Introductory lecture (31:24)
Drug target discovery - Definitions (8:15)
A brief history of drug target discovery (8:33)
A target-centric approach to drug discovery (8:55)
Drug development funnel (6:01)
Importance of the target selection phase (3:41)
Proteins and other types of biological molecules as targets
Who discovers targets in the modern world? (7:00)
Complexity and Diversity of target discovery work
Target selection criteria
Mechanisms of drug action (10:50)
Evidences of the target implication in the disease (11:24)
Therapeutic modalities and druggability (11:40)
Tissue specificity (8:48)
Target novelty vs. repurposing (11:22)
Target feasibility (12:37)
The target discovery landscape
Major achievements and failures of the pharma companies in the last 20 years (6:35)
Top pharma companies and their pipelines (6:00)
The most crowded and abandoned therapeutic areas: Phase transition success and likelihood of approval (8:22)
Innovation at 'big pharma' vs. 'small biotech' (4:44)
Successful repurposing within and across disease areas (4:52)
A computational approach to target discovery
Why use AI for target selection? (7:09)
Omics data types - advantages and downsides (7:30)
Use of biological graphs (11:33)
Text data and prior knowledge (13:08)
Examples of the tools for drug target discovery (11:53)
Applications of single cell data in drug discovery (9:55)
Omics data analysis put in the context of prior knowledge (5:03)
Challenges in multi-omics computational approaches to target selection (6:18)
Validation of computational approaches to target selection (9:06)
A computational approach in target discovery - Case studies
Previous attempts and growing role of computational methods to meet target selection criteria (14:16)
AI for target discovery (14:07)
AI for target discovery: Case studies (25:57)
PandaOmics target ID page (3:52)
Target combinations
Drug combinations: Advantages and downsides (10:11)
Synergistic vs. additive effects (5:11)
Oncology and synthetic lethality (17:29)
Robotic lab for the rapid discovery of combinations (14:55)
Discovery of drug combinations for auto-immune diseases (13:34)
Extended target discovery - Current and future trends
New therapeutic modalities (20:27)
Evolution of the druggable genome concept (10:49)
Untargeted to targeted - A re-evaluation of the mechanism of action and toxicity for old drugs (5:02)
Indication expansion and prioritisation (8:27)
Target discovery and senolytics (7:38)
Large language models in drug discovery (2:41)
Feedback
Please tell us what you think!